References
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD; 2017. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
- Lewis A, Torvinen S, Dekhuijzen PN, et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Serv Res. 2016;16:251.
- Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease among adults–United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:938–943.
- Centers for Disease Control and Prevention. COPD death rates in the United States, 1999-2014; 2014 [cited 2017 May 19]. Available from: http://www.cdc.gov/copd/data.html; National Vital Statistics System detailed mortality data at http://wonder.cdc.gov.
- Barr RG, Celli BR, Martinez FJ, et al. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med. 2005;118:1415.
- Foster JA, Yawn BP, Maziar A, et al. Enhancing COPD management in primary care settings. MedGenMed. 2007;9:24.
- Lavorini F, Levy ML, Corrigan C, et al. The ADMIT series - issues in inhalation therapy. Training tools for inhalation devices. Prim Care Respir J. 2010;19:335–341.
- Dekhuijzen PN, Bjermer L, Lavorini F, et al. Guidance on handheld inhalers in asthma and COPD guidelines. Respir Med. 2014;108:694–700.
- Bonini M, Usmani OS. The importance of inhaler devices in the treatment of COPD. COPD Research and Practice. 2015;1:9.
- Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2017;12:59–71.
- Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–371.
- Molimard M, Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2015;28:219–228.
- Rau JL. The inhalation of drugs: advantages and problems. Respir Care. 2005;50:367–382.
- Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):pii: 1601794.
- Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938.
- Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150:394–406.
- Souza ML, Meneghini AC, Ferraz E, et al. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J Bras Pneumol. 2009;35:824–831.
- Laube BL, Janssens HM, De Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–1331.
- Plaza V, Sanchis J, Roura P, et al. Physicians’ knowledge of inhaler devices and inhalation techniques remains poor in Spain. J Aerosol Med Pulm Drug Deliv. 2012;25:16–22.
- Jahedi L, Downie SR, Saini B, et al. Inhaler technique in asthma: how does it relate to patients’ preferences and attitudes toward their inhalers? J Aerosol Med Pulm Drug Deliv. 2017;30:42–52.
- Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249–254.
- Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J. 2009;18:243–249.
- Pepper AN, Cooke A, Livingston L, et al. Asthma and chronic obstructive pulmonary disease inhalers: techniques for proper use. Allergy Asthma Proc. 2016;37:279–290.
- Spiriva Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016. [cited June 06, 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206756s006lbl.pdf.
- Atrovent HFA [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012. [cited June 05, 2017]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Atrovent%20HFA/10003001_US_1.pdf.
- Bevespi Aerosphere [package insert]. Wilmington, DE: AstraZeneca LP; 2016. [cited June 05, 2017]. Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdf.
- ProAir HFA [package insert]. Frazer, PA:Teva Respiratory LLC; 2012. [cited June 05, 2017]. Available from: http://proair.com/hfa/library/docs/HFA_PI.pdf.
- Proventil HFA [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2014 [cited June 05, 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020503s046lbl.pdf.
- Ventolin HFA [package insert]. Research Triangle, NC: GlaxoSmithKline; 2014. [cited June 05, 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020983s032lbl.pdf.
- Xopenex HFA [package insert]. Marlborough, MA: Sunovion Pharmaceuticals; 2015 [cited June 05, 2017]. Available from: http://www.respistory.com/aa/ast/XOPENEX-HFA-Prescribing-Information.pdf.
- Symbicort [package insert]. Wilmington, DE: AstraZeneca LP; 2016. [cited June 05, 2017]. Available from: https://www.azpicentral.com/symbicort/symbicort.pdf#page=1.
- Serevent Diskus [package insert]. Research Triangle, NC: GlaxoSmithKline; 2016. [June 05, 2017]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Serevent_Diskus/pdf/SEREVENT-DISKUS-PI-MG-IFU.PDF.
- Advair Diskus [package insert]. Research Triangle, NC: GlaxoSmithKline; 2016. [cited June 05, 2017]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Advair_Diskus/pdf/ADVAIR-DISKUS-PI-MG-IFU.PDF.
- Breo Ellipta [package insert]. Research Triangle, NC: GlaxoSmithKline; 2016. [cited June 05, 2017]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Breo_Ellipta/pdf/BREO-ELLIPTA-PI-MG.PDF.
- Incruse Ellipta [package insert]. Research Triangle, NC: GlaxoSmithKline; 2016. [cited June 05, 2017]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Incruse_Ellipta/pdf/INCRUSE-ELLIPTA-PI-PIL.PDF.
- Anoro Ellipta [package insert]. Research Triangle, NC: GlaxoSmithKline; 2016. [cited June 05, 2017]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-MG.PDF.
- Spiriva Handihaler [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016. [cited June 05, 2017]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva/Spiriva.pdf.
- Arcapta Neohaler [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corporation; 2012. [cited June 05, 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf.
- Utibron Neohaler [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corporation; 2016. [cited June 05, 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207930s000lbl.pdf.
- Stiolto Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016. [cited June 05, 2017]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Stiolto%20Respimat/stiolto.pdf.
- Combivent Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016. [cited June 05, 2017]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Combivent%20Respimat/CMVTRSPT.pdf.
- Striverdi Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016. [cited June 05, 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206756s002lbl.pdf.
- ProAir Respiclick [package insert]. Frazer, PA:Teva Respiratory LLC; 2016. [cited June 05, 2017]. Available from: http://proair.com/hfa/library/docs/HFA_PI.pdf.
- Newman SP. Principles of metered-dose inhaler design. Respir Care. 2005;50:1177–1190.
- Aggarwal B, Gogtay J. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence. Expert Rev Respir Med. 2014;8:349–356.
- Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50: 1360–1374; discussion 1374–1365.
- Hatley RH, Parker J, Pritchard JN, et al. Variability in delivered dose from pressurized metered-dose inhaler formulations due to a delay between shake and fire. J Aerosol Med Pulm Drug Deliv. 2017;30:71–79.
- Mack P, Doty A, Schroeder J, et al. Drug delivery from a novel LAMA/LABA Co-Suspension Technology of glycopyrrolate/formoterol fixed-dose combination MDI: evidence of consistency, robustness and patient-use reliability. Am J Respir Crit Care Med. 2016;193:A5839–A5839.
- Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J. 1997;10:2127–2138.
- Biswas R, Hanania NA, Sabharwal A. Factors determining in vitro lung deposition of albuterol aerosol delivered by Ventolin metered-dose inhaler. J Aerosol Med Pulm Drug Deliv. 2017;30:255–266.
- Johal B, Howald M, Fischer M, et al. Fine particle profile of fluticasone propionate/formoterol fumarate versus other combination products: the DIFFUSE study. Combination Products in Therapy. 2013;3:39–51.
- Prime D, Grant AC, Slater AL, et al. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med. 1999;12:75–84.
- Al-Showair RAM, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101:2395–2401.
- Dekhuijzen PN, Vincken W, Virchow JC, et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respir Med. 2013;107:1817–1821.
- Scichilone N, Benfante A, Bocchino M, et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm Pharmacol Ther. 2015;31:63–67.
- Fink JB, Colice GL, Hodder R. Inhaler devices for patients with COPD. COPD. 2013;10:523–535.
- Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61:518–526.
- Yawn BP, Colice GL, Hodder R. Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2012;7:495–502.
- Amirav I, Newhouse MT. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics. 2001;108:389–394.
- Taffet GE, Donohue JF, Altman PR. Considerations for managing chronic obstructive pulmonary disease in the elderly. Clin Interv Aging. 2014;9:23–30.
- Georgopoulos D, Mouloudi E, Kondili E, et al. Bronchodilator delivery with metered-dose inhaler during mechanical ventilation. Crit Care. 2000;4:227–234.
- Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med. 2015;10:13.
- Price D, Bosnic-Anticevich S, Briggs A, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013;107:37–46.
- Azouz W, Chetcuti P, Hosker HS, et al. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28:35–42.
- Haidl P, Heindl S, Siemon K, et al. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med. 2016;118:65–75.
- Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36:213–218.
- Borgstrom L, Bondesson E, Moren F, et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:69–73.
- Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–139.
- Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593–604.
- Kunkel G, Magnussen H, Bergmann K, et al. Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration. 2000;67:306–314.
- Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1:251–259.
- Konstan MW, Sharma A, Moroni-Zentgraf P, et al. Safety, tolerability, and plasma exposure of tiotropium Respimat(R) in children and adults with cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 2015;28:137–144.
- Berry RB, Shinto RA, Wong FH, et al. Nebulizer vs spacer for bronchodilator delivery in patients hospitalized for acute exacerbations of COPD. Chest. 1989;96:1241–1246.
- Dhand R, Dolovich M, Chipps B, et al. The role of nebulized therapy in the management of COPD: evidence and recommendations. Copd. 2012;9:58–72.
- Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med. 1996;100:11S–18S.
- Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2011;68:1221–1232.
- Jarvis S, Ind PW, Thomas C, et al. Microbial contamination of domiciliary nebulisers and clinical implications in chronic obstructive pulmonary disease. BMJ Open Respir Res. 2014;1:e000018.
- Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respir Med. 2017;124:6–14.
- Pothirat C, Chaiwong W, Phetsuk N, et al. Evaluating inhaler use technique in COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:1291–1298.
- Tudorza Pressair [package insert]. Wilmington, DE: AstraZeneca LP; 2016. [cited June 05, 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202450s006lbl.pdf
- Broeders ME, Sanchis J, Levy ML, et al. The ADMIT series–issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J. 2009;18:76–82.
- Respimat®: A soft mist for easy inhalation. Boehringer Ingelheim. [June 05, 2017]. Available from: https://www.boehringer-ingelheim.com/products/prescription_medicines/respiratory/copd/spiriva/public/images/Patient-Tear-Sheet-BI-Pfizer-Release-Aug-1.pdf. September 2014.
- Dhand R. Inhaled drug therapy 2016: the year in review. Respir Care. 2017;62:978–996.
- Loh CH, Lovings T, Ohar J. Long acting nebulized agents decrease readmissions in patients with suboptimal peak inspiratory flow. Chest. 2016;150:925A–925A.
- Broeders ME, Molema J, Hop WC, et al. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98:1173–1179.
- Vanderman AJ, Moss JM, Bailey JC, et al. Inhaler misuse in an older adult population. Consult Pharm. 2015;30:92–100.
- Barrons RWJ, Woods JA. Opportunities for inhaler device selection in elderly patients with asthma or COPD. Patient Intelligence. 2015;7:53–65.
- Allen SC. Competence thresholds for the use of inhalers in people with dementia. Age Ageing. 1997;26:83–86.
- Allen SC, Ragab S. Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age. Postgrad Med J. 2002;78:37–39.
- Gray SL, Williams DM, Pulliam CC, et al. Characteristics predicting incorrect metered-dose inhaler technique in older subjects. Arch Intern Med. 1996;156:984–988.
- Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing. 2003;32:299–302.
- Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. Int J Chron Obstruct Pulmon Dis. 2016;11:597–602.
- Price D, Roche N, Christian Virchow J, et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med. 2011;105:1457–1466.
- Dal Negro RW, Povero M. Acceptability and preference of three inhalation devices assessed by the Handling Questionnaire in asthma and COPD patients. Multidiscip Respir Med. 2015;11:7.
- Roche N, Scheuch G, Pritchard JN, et al. Patient focus and regulatory considerations for inhalation device design: report from the 2015 IPAC-RS/ISAM workshop. J Aerosol Med Pulm Drug Deliv. 2017;30:1–13.
- Kawata AK, Kleinman L, Harding G, et al. Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD). Patient. 2014;7:413–426.
- Chorao P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD–an assessment of inhaler technique and patient preferences. Respir Med. 2014;108:968–975.
- Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435–441.
- Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med. 2000;94:496–500.
- Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831–838.
- Rogliani P, Ora J, Puxeddu E, et al. Adherence to COPD treatment: myth and reality. Respir Med. 2017;129:117–123.
- Sanduzzi A, Balbo P, Candoli P, et al. COPD: adherence to therapy. Multidiscip Respir Med. 2014;9:60.
- Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245.
- van Boven JF, Chavannes NH, Van Der Molen T, et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108:103–113.
- Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:371–384.
- Esposito S, Rosazza C, Sciarrabba CS, et al. Inhaled antibiotic therapy for the treatment of upper respiratory tract infections. J Aerosol Med Pulm Drug Deliv. 2017;30:14–19.
- Onoue S, Misaka S, Kawabata Y, et al. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opin Drug Deliv. 2009;6:793–811.
- Cogan PS, Sucher BJ. Appropriate use of pressurized metered-dose inhalers for asthma. US Pharmacist. 2015;40:36–41.
- Muralidharan P, Hayes D Jr., Mansour HM. Dry powder inhalers in COPD, lung inflammation and pulmonary infections. Expert Opin Drug Deliv. 2015;12:947–962.
- Stass H, Nagelschmitz J, Kappeler D, et al. Ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease, and in healthy volunteers. J Aerosol Med Pulm Drug Deliv. 2017;30:53–63.
- Wee WB, Tavernini S, Martin AR, et al. Dry powder inhaler delivery of tobramycin in in vitro models of tracheostomized children. J Aerosol Med Pulm Drug Deliv. 2017;30:64–70.
- Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26:174–179.
- Keating GM. Tiotropium Respimat(®) Soft Mist inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74:1801–1816.
- Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:1333–1343.
- Smith HS, Criner AJ, Fehrle D, et al. Use of a smartphone/tablet-based bidirectional telemedicine disease management program facilitates early detection and treatment of COPD exacerbation symptoms. Telemed J E Health. 2016;22:395–399.
- Chrystyn H, Niederlaender C. The Genuair(®) inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66:309–317.
- Su JG, Barrett MA, Henderson K, et al. Feasibility of deploying inhaler sensors to identify the impacts of environmental triggers and built environment factors on asthma short-acting bronchodilator use. Environ Health Perspect. 2017;125:254–261.
- Foster JM, Usherwood T, Smith L, et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. J Allergy Clin Immunol. 2014;134:1260–1268.e1263.
- Kuzma AM, Meli Y, Meldrum C, et al. Multidisciplinary care of the patient with chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:567–571.
- Leung J, Bhutani M, Leigh R, et al. Empowering family physicians to impart proper inhaler teaching to patients with chronic obstructive pulmonary disease and asthma. Can Respir J. 2015;22:266–270.
- Kshatriya RM, Khara NV, Paliwal RP, et al. Evaluation of proficiency in using different inhaler devices among intern doctors. J Family Med Prim Care. 2016;5:362–366.
- Self TH, Arnold LB, Czosnowski LM, et al. Inadequate skill of healthcare professionals in using asthma inhalation devices. J Asthma. 2007;44:593–598.
- Guidry GG, Brown WD, Stogner SW, et al. Incorrect use of metered dose inhalers by medical personnel. Chest. 1992;101:31–33.
- Takaku Y, Kurashima K, Ohta C, et al. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respir Med. 2017;123:110–115.
- Press VG, Arora VM, Shah LM, et al. Teaching the use of respiratory inhalers to hospitalized patients with asthma or COPD: a randomized trial. J Gen Intern Med. 2012;27:1317–1325.
- Bosnic-Anticevich SZ, Sinha H, So S, et al. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. J Asthma. 2010;47:251–256.
- Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, recommendations of the COPD Foundation. Copd. 2013;10:378–389.